MitraPro: A prospective registry study on 1-year mortality and the prognostic significance of MitraScore after MitraClip implantation in patients with mitral regurgitation

Conditions

I34.0

Rottländer D, Hausleiter J, Schmitz T, Bufe A, Seyfarth M, von Bardeleben RS, Beucher H, Ouarrak T, Schneider S, Boekstegers P, MITRA‐PRO Investigators.

2025-11-17

10.1161/jaha.125.044545

Residual Mitral Regurgitation Outweighs Mean Pressure Gradient in Predicting Long‐Term Survival After Transcatheter Edge‐to‐Edge Repair Across Mitral Regurgitation Etiologies

Dennis Rottländer, Jörg Hausleiter, Thomas Schmitz, Alexander Bufe, Melchior Seyfarth et al. (10 authors)

Catheterization and Cardiovascular Interventions2025-09-23

10.1002/ccd.70215

Intraprocedural 3D-vena contracta area predicts survival after transcatheter edge-to-edge repair: results from MITRA-PRO registry.

Rottländer D, Hausleiter J, Schmitz T, Bufe A, Seyfarth M, von Bardeleben RS, Beucher H, Ouarrak T, Schneider S, Boekstegers P, MITRA-PRO investigators.

2024-12-09

10.1007/s00392-024-02580-6

Intraprocedural Residual Mitral Regurgitation and Survival After Transcatheter Edge-to-Edge Repair: Prospective German Multicenter Registry (MITRA-PRO).

Boekstegers P, Hausleiter J, Schmitz T, Bufe A, Comberg T, Seyfarth M, Frerker C, Beucher H, Rottländer D, Higuchi S, Ouarrak T, Schneider S, MITRA-PRO Investigators.

2023-03-0118 citations

10.1016/j.jcin.2022.12.015

Interventions

Group 1: Patients with planned MitraClip implantation, who have given informed consent, are asked to fill in the SF-12 questionnaire prior to the procedure for quality of life assessment. In line with

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Severe mitral regurgitation; Implantation of one or more MitraClips intended by attending physicians; Informed consent form including the agreement on a telephone follow-up signed by the patient or their legally authorized representative

Exclusion criteria

Exclusion criteria: Accommodation in an institution due to court order or administrative order; since this study is a patient registry, there are no further exclusion criteria in order to avoid recruitment bias

Design outcomes

Primary

Measure	Time frame
1-year mortality [assessed by follow-up visit 12 months after MitraClip implantation or telephone Follow Up]	—

Secondary

Measure	Time frame
Change in MitraScore before and after MitraClip implantation [Periprocedural Calculation]; Rehospitalization rates [recording of all rehospitalization events for 12 months after MitraClip procedure]; Complication rates, particularly MACCE (Major Adverse Cardiac and Cerebrovascular Events) [recording of all events for 12 months after MitraClip procedure]; Subjective quality of life [assessed by SF-12 questionnaire before and within 12, 36 and 60 months after MitraClip procedure]; Non-determinability of MitraScore.	—

Measure

Time frame

Change in MitraScore before and after MitraClip implantation [Periprocedural Calculation]; Rehospitalization rates [recording of all rehospitalization events for 12 months after MitraClip procedure]; Complication rates, particularly MACCE (Major Adverse Cardiac and Cerebrovascular Events) [recording of all events for 12 months after MitraClip procedure]; Subjective quality of life [assessed by SF-12 questionnaire before and within 12, 36 and 60 months after MitraClip procedure]; Non-determinability of MitraScore.

—

Countries

Germany

Contacts

Public ContactRené Geißen

ZKS der Universität Witten/Herdecke

rene.geissen@uni-wh.de+492028965613

Outcome results

None listed